Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-8330. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 18/20 | 1.00 |
| ▸ | MAP2K2 known ✓ | P36507 | 3/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 1.00 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-8330 SCHEMBL29360392 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL391764 | 0.92 | MAP2K1 (0.85) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL18576802 | 0.90 | MAP2K1 (0.82) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL391636 | 0.90 | MAP2K1 (0.82) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL387711 | 0.90 | MAP2K1 (0.81) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL2341603 | 0.89 | MAP2K1 (0.80) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL393158 | 0.89 | MAP2K1 (0.79) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL12295137 | 0.89 | MAP2K1 (0.79) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL570183 | 0.89 | MAP2K1 (0.79) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 | |
| SCHEMBL392221 | 0.89 | MAP2K1 (0.79) | MAP2K1MAP2K2MAP2K5EIF2AK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2776 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028940-A | PI4K inhibitor and application thereof | 清华大学 | 2026-05-12 | — | — | CN | claimed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-20260002124-A1 | ENHANCING NEURONAL DIFFERENTIATION OF VENTRAL MIDBRAIN NEURAL PROGENITOR CELLS | NOVO NORDISK AS (DK) | 2026-01-01 | — | — | US | claimed |
| US-12509729-B2 | Compositions and methods for the diagnosis and treatment of lymphatic system disorders | THE CHILDREN'S HOSPTAL OF PHILADELPHIA (US) | 2025-12-30 | — | — | US | claimed |
| EP-3883579-B1 | COMBINATION THERAPY INCLUDING A KRAS-G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC (US) | 2025-12-24 | — | — | EP | claimed |
| US-20250340848-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | PEKING UNIVERSITY (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4611904-A1 | COMPOSITIONS AND METHODS FOR TREATING NF1 AND OTHER CONDITIONS | Liby, Karen (US) | 2025-09-10 | — | — | EP | claimed |
| US-20100004247-A1 | COMBINATION COMPRISING A MEK INHIBITOR AND AN AURORA KINASE INHIBITOR 188 | ASTRAZENECA AB (SE) | 2010-01-07 | — | — | US | claimed |
| US-20090291961-A1 | COMBINATION OF AN MEK INHIBITOR AND THE SRC KINASE INHIBITOR AZD0530 FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | US | claimed |
| WO-2009074827-A2 | COMBINATION COMPRISING A MEK INHIBITOR AND AN AURORA KINASE INHIBITOR 188 | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | WO | claimed |
| US-20090099174-A1 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | claimed |
| US-7517994-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-14 | — | — | US | claimed |
| US-20080280957-A1 | Heterocyclic Inhibitors of Mek and Methods of Use Thereof | ARRAY BIOPHARMA, INC. (US) | 2008-11-13 | — | — | US | claimed |
| WO-2008120004-A1 | COMBINATION OF A MEK- INHIBITOR AND A B-RAF INHIBITOR FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | WO | claimed |
| EP-1922307-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-05-21 | — | — | EP | claimed |
| WO-2007044084-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-04-19 | — | — | WO | claimed |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-17 | — | — | US | claimed |